

1128518

1632

PATENT

Attorney Docket No.014643-009031  
A-72015/GKS/THR

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

*In re application of:*  
**LONBERG, et al.**

Serial No. 09/724,965

Filed: November 28, 2000


For: *Transgenic Non-Human Animals  
for Producing Heterologous  
Antibodies*

Examiner: A.M.S. Wehbe

Art Unit: 1632

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including listed enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450  
on April 1, 2004

Signed:   
Traci H. Ropp

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants wish to draw the attention of the U.S. Patent and Trademark Office to the reference cited on the accompanying form PTO/SB/8A. Copies of the references are enclosed.

None of the foregoing references are believed to disclose the invention as claimed.

Nothing herein shall constitute an admission concerning the contents of any of the cited references, nor shall the inclusion of a reference herein be considered an admission that the reference constitutes prior art against the invention claimed in the above-identified application.

1128518\_1

04/07/2004 STANDARD 00000000 09724965  
01 FC:1806  
160.00 00

Serial No. 10/356,320  
Filing Date: January 30, 2003

Submission of the present document shall not be construed as an admission that a search has been made or that better art does not exist.

Pursuant to 37 C.F.R. §1.97(c), enclosed is a check in the amount of \$180.00 as set forth in 37 C.F.R. §1.17(p). The Commissioner is authorized to charge any additional fees which may be required, or credit any overpayment Deposit Account No. 50-2319 (Our Order No. A-72015/GKS/THR [455675-80]).

Respectfully submitted,

DORSEY & WHITNEY LLP

Date: April 1, 2004


  
Traci H. Ropp (Reg. No. 44,307)

Four Embarcadero Center, Suite 3400  
San Francisco, California 94111-4187  
Telephone: (415) 781-1989

**Customer Number 32940**

Attachments : Form PTO/SB/8A, Substitute for form 1449  
32 cited references  
Return Postcard

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  
(Modified)**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/724,965
Filing Date	November 28, 2000
First Named Inventor	LONBERG
Group Art Unit	1632
Examiner Name	A.M.S. Wehbe

Sheet	1	of	2	Attorney Docket Number	A-72015/GKS/ THR (455675-080))
-------	---	----	---	------------------------	--------------------------------

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	<b>ER</b>	5,545,806	08-13-1996	Lonberg, et al	
	<b>ES</b>	5,569,825	10-29-1996	Lonberg, et al	
	<b>ET</b>	5,591,669	01-07-1997	Krimpenfort et al	
	<b>EU</b>	5,612,205	03-18-1997	Kay et al.	
	<b>EV</b>	5,625,126	04-29-1997	Lonberg, et al	
	<b>EW</b>	5,661,016	08-26-1997	Lonberg, et al	
	<b>EX</b>	5,721,367	02-24-1998	Kay et al	
	<b>EY</b>	5,789,650	08-04-1998	Lonberg, et al	
	<b>EZ</b>	5,814,318	09-29-1998	Lonberg, et al	
	<b>FA</b>	5,939,598	08-17-1999	Kucherlapati et al	
	<b>FB</b>	6,023,010	02-08-2000	Krimpenfort et al	
	<b>FC</b>	6,075,181	06-13-2000	Kucherlapati et al	
	<b>FD</b>	6,150,584	11-21-2000	Kucherlapati et al	
	<b>FE</b>	6,162,963	12-19-2000	Kucherlapati et al	
	<b>FF</b>	6,114,598	09-05-2000	Kucherlapati et al	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	<b>FG</b>	WO 92/03917	03-19-1992	GenPharm Intl.		
	<b>FH</b>	WO 96/33735	10-31-1996	GenPharm Intl		
	<b>FI</b>	WO 97/13852	04-17-1997	GenPharm Intl		
	<b>FJ</b>	WO 98/24884	06-11-1998	GenPharm Intl		
	<b>FK</b>	WO 98/24893	06-11-1998	Abgenix		
	<b>FL</b>					

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	<b>FM</b>	Harding FA, Lonberg N., "Class switching in human immunoglobulin transgenic mice", <i>Ann N Y Acad Sci.</i> , 764: 536-46 (1995).	


- Examiner Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 1128514\_2

Substitute for form 1449A/PTO  
(Modified)**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/724,965
Filing Date	November 28, 2000
First Named Inventor	LONBERG
Group Art Unit	1632
Examiner Name	A.M.S. Wehbe

Sheet **2** of **2** Attorney Docket Number **A-72015/GKS/ THR (455675-080)****NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
FN	Jakobovits A , et al., "Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACs", <i>Ann N Y Acad Sci.</i> : 764:525-35 (1995)		
FO	Jakobovits A., "Production of fully human antibodies by transgenic mice", <i>Curr Opin Biotechnol.</i> : 6(5):561-6 (1995).		
FP	Jakobovits A, "YAC vectors. Humanizing the mouse genome", <i>Curr Biol.</i> , 4(8):761-3 (1994)		
FQ	Lonberg N., et al., "Antigen-specific human antibodies from mice comprising four distinct genetic modifications", <i>Nature</i> . 368(6474): 856-859 (1994)		
FR	Lonberg N, Huszar D., "Human antibodies from transgenic mice", <i>Int Rev Immunol.</i> 13(1): 65-93 (1995).		
FS	Storb, U. et al., "Expression of microinjected immunoglobulin kappa gene in transgenic mice", <i>Banbury Reports</i> , 20:197-207 (1985)		
FT	Takeda, S. et al, "Deletion of the immunoglobulin kappa chain intron enhancer abolishes kappa chain gene rearrangement <i>in cis</i> but not lambda chain gene rearrangement <i>in trans</i> ", <i>EMBO J.</i> , 12(6): 2329-2336 (1993)		
FU	Taylor, L.D. et al, "A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins", <i>Nucl. Acids Res.</i> , 20:6287-6295, (1992)		
FV	Taylor, L.D. et al, "Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM", <i>Intl. Immunol.</i> , 6(4):579-591 (1994)		
FW	Tualllon, N. et al., "Human immunoglobulin heavy-chain minilocus recombination in transgenic mice: gene-segment use in mu and gamma transcripts " <i>PNAS</i> , 90:3720-3724		
FX	Zou, Y-R., et al., "Gene targeting in the Ig kappa locus: Efficient generation of lambda chain-expressing B cells, independent of gene rearrangements in Ig kappa", <i>EMBO J.</i> , 12(3):811-820 (1993)		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST-16, if possible.

<sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 1128514\_2